Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Jefferies analyst Roger Song downgraded the rating for Verve Therapeutics, Inc. (NASDAQ:VERV) from Buy to Hold and lowered the price target from $28 to $11. Verve Therapeutics shares closed at $11.38 on Tuesday. See how other analysts view this stock.
- LifeSci …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Jefferies analyst Roger Song downgraded the rating for Verve Therapeutics, Inc. (NASDAQ:VERV) from Buy to Hold and lowered the price target from $28 to $11. Verve Therapeutics shares closed at $11.38 on Tuesday. See how other analysts view this stock.
- LifeSci …
Full story available on Benzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Jefferies analyst Roger Song downgraded the rating for Verve Therapeutics, Inc. (NASDAQ:VERV) from Buy to Hold and lowered the price target from $28 to $11. Verve Therapeutics shares closed at $11.38 on Tuesday. See how other analysts view this stock.
LifeSci …Full story available on Benzinga.com Read MoreEM, News, Top Downgrades, VERV, Downgrades, Pre-Market Outlook, Markets, Trading Ideas, EM, VERV, News, Downgrades, Pre-Market Outlook, Markets, Trading Ideas, Benzinga Markets
